DDX3Y and Burkitt lymphoma: The main challenge with this concept remains the high similarity between DDX3X and DDX3Y, but if a strategy could be devised in which DDX3Y could be targeted over DDX3X, the benefits for male BL and DLBCL patients with DDX3X LOF mutations would be significant and could give rise to the development of a novel cancer cell-specific therapy.